
Unlocking TIL Therapy: A New Era for Melanoma Care in the UK
Advances in cancer immunotherapy are transforming the way melanoma is treated worldwide. One of the most promising developments is Tumour-Infiltrating Lymphocyte (TIL) therapy, an innovative treatment approach that harnesses the body’s own immune system to target and destroy cancer cells. To explore this emerging therapy and its potential impact on patient care, leading experts recently gathered in Manchester for the Unlocking TIL Therapy: A New Era for Melanoma Care in the UK Conference, hosted by The Christie Institute for Cancer Education.
Held at the prestigious The Midland Hotel on 11 March 2026, the conference brought together clinicians, researchers, and healthcare professionals committed to advancing melanoma treatment in the UK.
What Is TIL Therapy?
TIL therapy is a form of adoptive cell therapy, a cutting-edge immunotherapy that uses immune cells taken directly from a patient’s tumour. These specialised immune cells—known as tumour-infiltrating lymphocytes—are isolated, expanded in the laboratory, and then reintroduced into the patient to help the immune system recognise and attack cancer cells more effectively.
This approach has shown encouraging results in clinical studies, particularly for patients with advanced melanoma who may not respond to conventional treatments. As research progresses, TIL therapy is expected to play an increasingly important role in the future of personalised cancer care.
Expert Speakers Leading the Discussion
The conference featured an outstanding panel of internationally recognised experts, each bringing valuable insight into melanoma management and immunotherapy research.
Key speakers included:
Dr Rebecca Lee – Consultant Medical Oncologist
Mr Deemesh Oudit – Consultant Plastic & Reconstructive Surgeon
Prof Samra Turajlic – Professor of Medical Oncology & Cancer Researcher
Dr Andrew Furness – Consultant Medical Oncologist
Prof Inge Marie Svane – Professor of Clinical Cancer Immunology
Dr Brent O’Carrigan – Consultant Medical Oncologist
Together, the faculty explored the latest research developments, clinical trial data, and the practical challenges of implementing TIL therapy within the UK healthcare system.
The Future of Melanoma Treatment
Melanoma remains one of the most aggressive forms of skin cancer, but rapid progress in immunotherapy is offering new hope for patients. Treatments such as checkpoint inhibitors have already transformed outcomes for many individuals, and TIL therapy represents the next wave of innovation in this field.
Events like this conference play a crucial role in sharing knowledge, encouraging collaboration, and accelerating the translation of scientific breakthroughs into real-world patient care.
As research continues to advance, the integration of therapies like TIL into clinical practice could mark a significant milestone in the fight against melanoma.
Contact Mr. Oudit
Schedule Your Consultation with Dr. Deemesh Oudit!
Take the first step towards transforming your health and appearance. Schedule a free consultation with Dr. Oudit to discuss your treatment options and how we can help you achieve your goals.

